Qingdao University

About: Qingdao University is a education organization based out in Qingdao, China. It is known for research contribution in the topics: Cancer & Apoptosis. The organization has 35675 authors who have published 27275 publications receiving 374908 citations. The organization is also known as: Qīngdǎo Dàxué.

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial

Abstract: In China, colorectal cancer is the fifth most common malignancy in men and the sixth most common malignancy in women[1]. In 2008, colorectal cancer was the fifth most common cause of tumor death in men and women, accounting for 5.6% of the total deaths due to cancer[1]. Current recommended chemotherapy for metastatic colorectal cancer (mCRC) in China is fluoropyrimidine-based chemotherapy, with the addition of oxaliplatin or irinotecan (FOLFOX/FOLFIRI/CapeOx). Randomized clinical trials have shown that in patients with previously untreated mCRC, bevacizumab improves progression-free survival (PFS) and overall survival (OS) in combination with irinotecan-based[2] or 5-fluorouracil (5-FU)–based chemotherapy[3] and improves PFS in combination with oxaliplatin-based chemotherapy[4]. Furthermore, combination of bevacizumab with 5-FU–based chemotherapy has been shown to improve PFS compared with 5-FU–based chemotherapy alone in the second-line treatment of patients with mCRC[5]. However, there is a paucity of data from large phase III clinical trials on the effect of the combination of bevacizumab with chemotherapy in Chinese patients with mCRC. Three large observational studies in patients with mCRC have shown that the efficacy and safety profile of bevacizumab in routine clinical practice is consistent with results observed in prospective randomized clinical trials[6]–[9]. However, as with the randomized phase III trials, these observational studies did not include Chinese patients. This phase III trial—avastin and irinotecon in first-line metastatic colorectal cancer (China ARTIST)— was performed to evaluate whether the benefits observed in Caucasian patients following the addition of bevacizumab to irinotecan-based chemotherapy in a pivotal phase III trial[2] and a phase IV trial[10] could be replicated in Chinese patients with mCRC undergoing first-line therapy with bevacizumab in combination with modified irinotecan, leucovorin bolus, and 5-FU intravenous infusion (mIFL) compared with mIFL alone.